← Back to Home

A Tailored Therapy for Rare Inherited ALS: GBFsen Has Now Been Given to Two Patients in the Same Family

With less than a year from diagnosis to first dosing, a personalized antisense therapy has crossed the threshold into human use. A second family member carrying the same mutation has now also received treatment, but no public clinical results are available to assess whether it can slow the disease or how large the risks may be.

By SURL BioNews

For patients with rapidly progressing amyotrophic lateral sclerosis (ALS) and an extremely rare disease-causing mutation, identifying the cause often still leaves a long road to developing a treatment. GBFsen, a personalized antisense oligonucleotide therapy developed by La Jolla Labs, was first administered less than a year after the first patient was diagnosed. An October 22 announcement from the American Society of Human Genetics (ASHG) further reported that another diagnosed patient in the same family, carrying the same mutation, had also received treatment.

The program targets a specific pathogenic variant in the TARDBP gene, which encodes the TDP-43 protein. According to the company, the first patient's mutation lies in the protein's prion-like domain. GBFsen is a short nucleic acid sequence designed for that mutation, intended to selectively act on the relevant RNA transcripts and intervene in the disease mechanism upstream of protein production. This design has a clearly defined scope of application and cannot be directly extended to other mutations or all patients with ALS.

The first dose was administered before this latest society announcement. La Jolla Labs had already announced on April 30 that the first patient had received treatment, stating that the program began in September 2025 and entered clinical development at Heidelberg University Hospital in Germany after review by the 1M1M consortium in March 2026. This timeline illustrates the speed of establishing a treatment approach for a single rare mutation; it does not provide evidence that efficacy has been validated.

The specific role of artificial intelligence was to help screen antisense oligonucleotide candidates capable of selectively recognizing the target. ASHG stated that the candidates underwent preclinical evaluation and translational review before dosing; the September 24 RNA Leaders USA agenda had also listed this rapid development program. However, these public materials do not disclose the AI training data, predictive performance, or complete experimental data, making it difficult to assess how much development time AI actually saved or whether the screening results can be reproduced for other mutations.

This effort also involves the resources needed to develop drugs for rare diseases. The company said it funded the program, with support from Illumina, ChemGenes Corporation, and IDT. When patient numbers are too small to sustain traditional commercial development, such collaborations offer another way forward. However, no cost data are currently public, so it is not yet possible to conclude that the same model could be used widely at an affordable cost.

The most critical gap remains the actual changes in patients after treatment. Safety, tolerability, and exploratory biomarkers are still being evaluated, and no clinical results have been released. It is therefore not possible to determine whether GBFsen improves function, slows deterioration, or causes any adverse reactions. The company's April announcement also explicitly stated that GBFsen remains an investigational therapy and has not been approved by the U.S. Food and Drug Administration.

The research team plans to make treatment available to other family members and ALS patients carrying the same mutation. Dosing the second patient takes the program beyond the initial case, but the experience of two patients from the same family remains insufficient to establish safety and efficacy. Continued follow-up and clinical data available for scrutiny will be needed to determine whether this shortened drug development journey can also change the course of the disease.

References

  1. American Society of Human Genetics
  2. La Jolla Labs, Inc. via BioSpace
  3. Informa Connect — RNA Leaders USA